Brief: Aim Immunotech Announces First Subject Dosed In The Netherlands For Phase 1B/2 Study Evaluating Ampligen®
14/02/2024 16:47
Feb 14 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH ANNOUNCES FIRST SUBJECT DOSED IN THE
NETHERLANDS
FOR PHASE 1B/2 STUDY EVALUATING AMPLIGEN® (RINTATOLIMOD) IN
COMBINATION WITH ASTRAZENECA’S IMFINZI (DURVALUMAB) FOR THE
TREATMENT OF PANCREATIC CANCER
* PHASE 1B PORTION OF STUDY EXPECTED TO BE COMPLETED WITHIN
SIX
MONTHS
* STUDY IS EXPECTED TO ENROLL UP TO 18 SUBJECTS IN ITS PHASE
1B
PORTION AND UP TO 25 SUBJECTS IN ITS PHASE 2 PORTION
Source text for Eikon: ID:nGNE7vYkRQ
Further company coverage: AIM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential